F-18-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma
This study aimed to determine whether F-18-FDG PET response after induction chemotherapy before concurrent chemoradiotherapy can identify patients with esophageal adenocarcinoma who may benefit from subsequent esophagectomy. Methods: We identified and analyzed 220 patients with esophageal adenocarcinoma who had received induction chemotherapy before chemoradiotherapy, with or without surgery, with curative intent; all underwent F-18-FDG PET scanning before and after induction chemotherapy. F-18-FDG PET responders were defined as patients who achieved complete response (CR) after induction chemotherapy (maximum SUV <= 3.0). The predictive value of F-18-FDG PET response for patient outcomes was evaluated. Results: Overall, 86 patients had bimodality therapy (BMT; induction chemotherapy + chemoradiotherapy) and 134 had trimodality therapy (TMT; induction chemotherapy + chemoradiotherapy with surgery). Forty-eight patients (21.8%) achieved an F-18-FDG PET CR after induction chemotherapy. F-18-FDG PET CR was found to correlate with overall survival (OS) and progression-free survival (PFS) in BMT patients. For TMT patients, F-18-FDG PET CR predicted pathologic response (P = 0.003) but not survival. Among F-18-FDG PET nonresponders, TMT patients had significantly better survival than did BMT patients (P < 0.001). However, among F-18-FDG PET responders, BMT patients had OS (P = 0.201) and PFS (P 5 0.269) similar to that of TMT patients. After propensity scorematched analysis, F-18-FDG PET responders treated with BMT versus TMT still had comparable OS and PFS, but TMT was associated with better locoregional control. Conclusion: F-18-FDG PET response to induction chemotherapy could be a useful imaging biomarker to identify patients with esophageal adenocarcinoma who could benefit from subsequent esophagectomy after chemoradiotherapy. Compared with BMT, TMT can significantly improve survival in F-18-FDG PET nonresponders. However, outcomes for F-18-FDG PET responders were similar after either treatment (BMT or TMT). Prospective validation of these findings is warranted.
基金:
National Cancer Institute Cancer CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA016672]; Elekta; STCube Pharmaceuticals; Peregrine Pharmaceuticals; Hitachi Chemical; Roche/GenentechRoche HoldingGenentech
语种:
外文
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类|1 区医学
小类|1 区核医学
最新[2023]版:
大类|1 区医学
小类|2 区核医学
第一作者:
第一作者机构:[1]Sun Yat Sen Univ, Dept Radiat Oncol, State Key Lab Oncol South China, Canc Ctr,Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China;
通讯作者:
通讯机构:[2]Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 97,1515 Holcombe Blvd, Houston, TX 77030 USA;
推荐引用方式(GB/T 7714):
Xi Mian,Liao Zhongxing,Hofstetter Wayne L.,et al.F-18-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma[J].JOURNAL OF NUCLEAR MEDICINE.2017,58(11):1756-1763.doi:10.2967/jnumed.117.192591.
APA:
Xi, Mian,Liao, Zhongxing,Hofstetter, Wayne L.,Komaki, Ritsuko,Ho, Linus&Lin, Steven H..(2017).F-18-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.JOURNAL OF NUCLEAR MEDICINE,58,(11)
MLA:
Xi, Mian,et al."F-18-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma".JOURNAL OF NUCLEAR MEDICINE 58..11(2017):1756-1763